Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy

Abstract Background Targeting the tumor microenvironment (TME) has emerged as a promising strategy in cancer treatment, particularly through the utilization of immune checkpoint blockade (ICB) agents such as PD-1/PD-L1 inhibitors. Despite partial success, the presence of tumor-associated macrophages...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Shengzhe Jin, Hongfei Wang, Yang Li, Jingwen Yang, Beibei Li, Peishang Shi, Xiangrui Zhang, Xiaowen Zhou, Xiuman Zhou, Xiaoshuang Niu, Menghan Wu, Yahong Wu, Wenjie Zhai, Yuanming Qi, Yanfeng Gao, Wenshan Zhao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-03-01
coleção:	Cell Communication and Signaling
Assuntos:	Tumor microenvironment Immune checkpoint blockade PD-1/PD-L1 CD47/SIRPα Radiotherapy
Acesso em linha:	https://doi.org/10.1186/s12964-024-01555-4
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!